We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Urine Trumps Blood For Zika Testing

By LabMedica International staff writers
Posted on 08 Jun 2016
Print article
Image: A female Aedes aegypti mosquito, a vector of the Zika virus, obtaining a blood meal from a human host (Photo courtesy of James Gathany / CDC).
Image: A female Aedes aegypti mosquito, a vector of the Zika virus, obtaining a blood meal from a human host (Photo courtesy of James Gathany / CDC).
Limited data suggest Zika virus is excreted in multiple body fluids, including urine and saliva and that urine and saliva might be more appropriate specimens than blood samples for evaluating Zika virus disease.

The interim diagnostic testing guidance for the Zika virus recommends real-time reverse transcription-polymerase chain reaction (rRT-PCR) testing for urine specimens obtained two weeks after the illness starts. The Zika virus ribonucleic acid (RNA) is almost undetectable in blood samples after the first week of illness.

Scientists from the Centers for Disease Control and Prevention (CDC, Atlanta GA, USA) and their colleagues collected multiple specimen types from persons with suspected Zika virus disease. Urine specimens were collected from 70 patients with suspected Zika virus disease from zero to 20 days after symptom onset. In 66 cases, persons had urine and serum specimens collected on the same day. The majority of these persons were female (64%), white (77%), and Hispanic (71%), with a median age of 46 years, age range 23 to76 years.

Zika virus rRT-PCR was performed at the Bureau of Public Health Laboratories (BPHL, Tampa, FL, USA) using a laboratory-developed test based on a previously published protocol using two RT-PCR targets. The teams found urine samples were the best at flagging Zika, with 93% of specimens collected within 20 days of symptoms first appearing showing positive results. Urine specimens also displayed positive results 82% of the time when samples were collected more than five days after symptoms cropped up. Urine samples were positive 95% of the time when the specimens were obtained the same day or within five days of illness onset as compared to 56% for blood samples.

The authors concluded that the results of testing conducted suggest that urine might be the preferred specimen type to identify acute Zika virus disease. Rates of detection from urine were higher than from serum, even during the first few days after symptom onset and continuing after day five, when no serum specimens tested in this evaluation had detectable RNA. Among pregnant women, this ability to confirm Zika virus is important because close monitoring during pregnancy is recommended for women with confirmed Zika virus disease.

The ease of collection of urine specimens is an additional advantage. This report also demonstrated that saliva specimens (another specimen that is easily obtained) can also yield a higher rate of RNA detection than serum even during the first five days; the detection rate in saliva also approaches the detection rate in urine. However, no cases were identified through saliva testing alone. The study was published on May 13, 2016, in the journal Morbidity and Mortality Report.

Related Links:
Centers for Disease Control and Prevention
Bureau of Public Health Laboratories

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.